Acide tranexamique oral dans le traitement du lichen pigmentogène

Zenjari, L.; Elfetoiki, F.Z.; Hali, F.; Skalli, Hayat Dahbi; Chiheb, Soumiya

doi:10.1016/j.annder.2020.06.017

Cited by 5 publications

(4 citation statements)

References 12 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Oral tranexamic acid has been found helpful in a couple of studies for lichen planus pigmentosus and Riehl's melanosis. Tranexamic acid at a dose of 250 mg once daily for 4–6 months led to partial improvement in pigmentation in 50% (10/20) of cases of lichen planus pigmentosus 34 . A combination of tranexamic acid 250 mg twice daily and oral glycyrrhizin 50 mg thrice daily for 3 months led to 70% (7/10) of patients with Riehl's melanosis having 51–75% improvement in pigmentation 35 …”

Section: Treatment Of Admhmentioning

confidence: 99%

“…Tranexamic acid at a dose of 250 mg once daily for 4-6 months led to partial improvement in pigmentation in 50% (10/20) of cases of lichen planus pigmentosus. 34 A combination of tranexamic acid 250 mg twice daily and oral glycyrrhizin 50 mg thrice daily for 3 months led to 70% (7/10) of patients with Riehl's melanosis having 51-75% improvement in pigmentation. 35 The effectiveness of lasers in the treatment of dermal pigmentary disorders in different ethnic skin types has been listed in…”

Section: Treatments Tried In Various Studiesmentioning

confidence: 99%

See 1 more Smart Citation

Acquired dermal macular hyperpigmentation: an overview of the recent updates

Shah,

Baskaran,

Vinay

et al. 2023

Int J Dermatology

View full text Add to dashboard Cite

Acquired dermal macular hyperpigmentation (ADMH), previously known as macular pigmentation of uncertain etiology (MPUE), is an umbrella concept that unifies the distinct but overlapping acquired dermal pigmentary disorders like lichen planus pigmentosus, ashy dermatosis, erythema dyschromicum perstans, Riehl’s melanosis and pigmented contact dermatitis. All of these disorders usually lack a clinically apparent inflammatory phase, are characterised by dermal pigmentation clinically and histologically, and have a variable protracted disease course. Recently, a proposal has been made to classify these disorders into those with and without contact sensitisation. Dermoscopy is essentially similar across the spectrum of these disorders, and is useful for diagnosis and therapeutic response monitoring. Scoring system has been validated for the same. The treatment of ADMH remains challenging, with multiple topicals, oral therapies including mycophenolate mofetil, and lasers tried. Need of the hour is randomised controlled trials to enhance the therapeutic armamentarium.

show abstract

Section: Treatment Of Admhmentioning

confidence: 99%

Section: Treatments Tried In Various Studiesmentioning

confidence: 99%

Acquired dermal macular hyperpigmentation: an overview of the recent updates

Shah,

Baskaran,

Vinay

et al. 2023

Int J Dermatology

View full text Add to dashboard Cite

show abstract

“…Zenjari et al 16 demonstrated the therapeutic efficacy of oral TA in 20 patients with LPP; they prescribed 250 mg/daily oral TA for 4–6 months. At follow‐up, 10 patients showed partial improvement, three patients had no improvement, and seven patients were lost to follow‐up.…”

Section: Literature Reviewmentioning

confidence: 99%

“…The remaining patients have slight or no improvement. 15 Zenjari et al 16 in the treatment of recalcitrant Riehl's melanosis, which is a form of contact dermatitis that presents as facial brown or bluish reticulate pigmentation, mainly on the forehead and temporal regions.…”

Section: Ta B L E 1 (Continued)mentioning

confidence: 99%

Oral tranexamic acid in the treatment of hyperpigmentation disorder beyond melasma: A review

Mahjoub

Milibary²

2022

J of Cosmetic Dermatology

View full text Add to dashboard Cite

Tranexamic acid (TA), a synthetic derivative of the amino acid lysine, is an antifibrinolytic, procoagulant agent that the Food and Drug Administration approves for the treatment of cyclic heavy menstrual bleeding and prevention of bleeding in patients with hemophilia undergoing tooth extractions. 1 Oral TA has been used off-label in dermatology in the treatment of melasma and other hyperpigmentation disorders. 2 In a recent study, oral TA has been reviewed thoroughly in treating melasma, and its effectiveness has been demonstrated. 2 Their role in treating other hyperpigmentation disorders has also been tried in several studies. The present review discusses the emerging role of oral TA in the treatment of hyperpigmentation disorders other than melasma.

show abstract